|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM364133627 |
| 003 |
DE-627 |
| 005 |
20231227135926.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202305992
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1235.xml
|
| 035 |
|
|
|a (DE-627)NLM364133627
|
| 035 |
|
|
|a (NLM)37921507
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Liu, Zhen
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A Counterion-Free Strategy for Chronic Metabolic Acidosis Based on an Orally Administered Gut-Restricted Inorganic Adsorbent
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 22.12.2023
|
| 500 |
|
|
|a Date Revised 22.12.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Chronic metabolic acidosis, arising as a complication of chronic kidney disease (CKD), not only reduces patients' quality of life but also aggravates renal impairment. The only available therapeutic modality, involving intravenous infusion of NaHCO3 , engenders undesirable sodium retention, thereby increasing hemodynamic load and seriously exacerbating the primary disease. This deleterious cascade extends to the development of cardiovascular diseases. Herein, an orally administered, gut-restricted inorganic adsorbent that can effectively alleviate chronic metabolic acidosis without causing any electrolytic derangement or superfluous cardiovascular strain is developed. The genesis of ABC-350 entails the engineering of bismuth subcarbonate via annealing, thereby yielding a partially β-Bi2 O3 -doped (BiO)2 CO3 biphasic crystalline structure framework enriched with atomic vacancies. ABC-350 can selectively remove chloride ions and protons from the gastrointestinal tract, mimicking the physiological response to gastric acid removal and resulting in increased serum bicarbonate. Owing to its gut-restricted nature, ABC-350 exhibits commendable biosafety, averting undue systemic exposure. In two rat models of metabolic acidosis, ABC-350 emerges not only as a potent mitigator of acidosis but also effects discernible amelioration concerning proximal tubular morphology, interstitial fibrosis, and the incendiary cascades incited by metabolic acidosis. ABC-350, as the translationally relevant material, provides a promising strategy for the treatment of metabolic acidosis
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a chronic kidney disease
|
| 650 |
|
4 |
|a chronic metabolic acidosis
|
| 650 |
|
4 |
|a gut-restricted drug
|
| 650 |
|
4 |
|a orally administered adsorbent
|
| 650 |
|
7 |
|a Protons
|2 NLM
|
| 700 |
1 |
|
|a Xiang, Liang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tian, Meng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Haoyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Xin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Kangfei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Jia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Tianzhi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Shangpeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mu, Xin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Bingxue
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Shiyi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Luo, Jie
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 35(2023), 51 vom: 22. Dez., Seite e2305992
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:35
|g year:2023
|g number:51
|g day:22
|g month:12
|g pages:e2305992
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202305992
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2023
|e 51
|b 22
|c 12
|h e2305992
|